Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jan 15;209(2):223-224.
doi: 10.1164/rccm.202307-1143LE.

Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective

Qiming Gan  1 , Yanjuan Wu  1 , Xiaofen Su  1 , Jingcun Wang  1 , Haojie Zhang  1 , Nuofu Zhang  1 , Kang Wu  1
Affiliations
Comment

Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective

Qiming Gan et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment in

  • Reply to Gan et al., to Calzetta et al., and to Poor.
    Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F. Anzueto A, et al. Am J Respir Crit Care Med. 2024 Jan 15;209(2):226-228. doi: 10.1164/rccm.202309-1657LE. Am J Respir Crit Care Med. 2024. PMID: 37939377 Free PMC article. No abstract available.

Comment on

References

    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease; 2022. https://goldcopd.org/wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2...
    1. Zuo H, Cattani-Cavalieri I, Musheshe N, Nikolaev VO, Schmidt M. Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacol Ther . 2019;197:225–242. - PubMed
    1. Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials) Am J Respir Crit Care Med . 2023;208:406–416. - PMC - PubMed
    1. Singh D, Lea S, Mathioudakis AG. Inhaled phosphodiesterase inhibitors for the treatment of chronic obstructive pulmonary disease. Drugs . 2021;81:1821–1830. - PubMed
    1. Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FME, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J . 2018;52:1801219. - PubMed

MeSH terms